TWD 70.8
(0.28%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 24.58 Million TWD | 70.79% |
2022 | 14.39 Million TWD | 76.07% |
2021 | 8.17 Million TWD | 105.35% |
2020 | 3.98 Million TWD | -74.7% |
2019 | 15.73 Million TWD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 3.7 Million TWD | 38.88% |
2024 Q1 | 2.66 Million TWD | -57.88% |
2023 Q3 | 6.33 Million TWD | -21.47% |
2023 FY | 24.58 Million TWD | 70.79% |
2023 Q2 | 8.06 Million TWD | 108.91% |
2023 Q1 | 3.86 Million TWD | 24.76% |
2023 Q4 | 6.33 Million TWD | 0.0% |
2022 FY | 14.39 Million TWD | 76.07% |
2022 Q4 | 3.09 Million TWD | 0.0% |
2021 FY | 8.17 Million TWD | 105.35% |
2020 FY | 3.98 Million TWD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Apex Biotechnology Corp. | 1.67 Billion TWD | 98.533% |
Sinphar Pharmaceutical Co.,Ltd. | 2.96 Billion TWD | 99.17% |
Panion & Bf Biotech Inc. | 1.88 Billion TWD | 98.693% |
Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 2.08 Billion TWD | 98.821% |
GenMont Biotech Incorporation | 318.01 Million TWD | 92.268% |
Abnova (Taiwan) Corporation | 382.05 Million TWD | 93.564% |
Adimmune Corporation | 1.78 Billion TWD | 98.623% |
Tanvex BioPharma, Inc. | 61.41 Million TWD | 59.96% |
Polaris Group | 7.48 Million TWD | -228.686% |
Energenesis Biomedical CO.,LTD. | 7.15 Million TWD | -243.518% |
PELL Bio-Med Technology Co. Ltd. | 18.03 Million TWD | -36.356% |